Related Experiment Video

Updated: Dec 27, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.6K

PARP Inhibitors in Prostate and Urothelial Cancers

Rohan Garje1, Raju Kumar Vaddepally2, Yousef Zakharia1

  • 1Division of Hematology, Oncology, and Blood and Marrow Transplant, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, United States.

Frontiers in Oncology
|March 3, 2020
PubMed

Insights

Poly(ADP-ribose) polymerase (PARP) inhibitors show promise for treating advanced prostate and urothelial cancers with DNA repair gene mutations. Ongoing trials are evaluating PARP inhibitors alone and in combination therapies.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Poly(ADP-ribose) polymerase (PARP) inhibitors are effective in ovarian and breast cancers with DNA repair gene mutations.
  • Approximately 20% of metastatic prostate cancers harbor DNA repair gene mutations, indicating potential for PARP inhibitor therapy.

Purpose of the Study:

  • To review the rationale, efficacy, and safety of PARP inhibitors in prostate and urothelial cancers.
  • To summarize current clinical trial data for PARP inhibitors in these cancer types.

Main Methods:

  • Comprehensive literature review of preclinical and clinical studies.
  • Analysis of efficacy and safety data from PARP inhibitor trials.

Main Results:

  • Early phase studies demonstrate clinical activity of PARP inhibitors in prostate cancer.
  • Numerous clinical trials are investigating PARP inhibitors in monotherapy and combination regimens for prostate cancer.

Conclusions:

  • PARP inhibitors represent a promising therapeutic strategy for prostate and urothelial cancers with specific DNA repair gene alterations.
  • Further clinical investigation is warranted to establish the role of PARP inhibitors in these malignancies.
Keywords:
DNA damage repair genesPARP inhibitorprecision oncologyprosate cancerurothelial cancer (UC)

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.1K
Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

10.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
386
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
456